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Implications for depression?
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Background: Psychological stress, particularly in chronic form, can lead to mood and cognitive dysfunction and is a
major risk factor in the development of depressive states. How stress affects the brain to cause psychopathologies
is incompletely understood. We sought to characterise potential depression related mechanisms by analysing gene
expression and molecular pathways in the infralimbic medial prefrontal cortex (ILmPFC), following a repeated
psychological stress paradigm. The ILmPFC is thought to be involved in the processing of emotionally contextual
information and in orchestrating the related autonomic responses, and it is one of the brain regions implicated in
both stress responses and depression.
Results: Genome-wide microarray analysis of gene expression showed sub-chronic restraint stress resulted
predominantly in a reduction in transcripts 24 hours after the last stress episode, with 239 genes significantly
decreased, while just 24 genes had increased transcript abundance. Molecular pathway analysis using DAVID
identified 8 pathways that were significantly enriched in the differentially expressed gene list, with genes belonging
to the brain-derived neurotrophic factor – neurotrophin receptor tyrosine kinase 2 (BDNF-Ntrk2) pathway most
enriched. Of the three intracellular signalling pathways that are downstream of Ntrk2, real-time quantitative PCR
confirmed that only the PI3K-AKT-GSK3B and MAPK/ERK pathways were affected by sub-chronic stress, with the
PLCγ pathway unaffected. Interestingly, chronic antidepressant treatment with the selective serotonin reuptake
inhibitor, fluoxetine, prevented the stress-induced Ntrk2 and PI3K pathway changes, but it had no effect on the
MAPK/ERK pathway.
Conclusions: These findings indicate that abnormal BDNF-Ntrk2 signalling may manifest at a relatively early time
point, and is consistent with a molecular signature of depression developing well before depression-like behaviours
occur. Targeting this pathway prophylactically, particularly in depression-susceptible individuals, may be of
therapeutic benefit.
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Stress is a potent risk factor in the development of
mood and anxiety disorders and other psychopatholo-
gies. For example, stress is an important non-genetic
cause of major depressive disorder (MDD), with both
acute and chronic forms capable of precipitating major
depressive episodes [1,2]. A number of theories have
been proposed to explain how stress alters brain struc-
ture and function in stress responsive areas [3] and
there is compelling evidence for synaptic plasticity dys-
regulation, with much work having elucidated how the
glucocorticoid and various neurotransmitter systems
contribute to this dysregulation (for reviews see [4-9]).
In order to better understand how stress affects brain
function, we have previously used a chronic psycho-
logical stress model and found that this stress para-
digm markedly upregulates deltaFosB expression, a
marker of ongoing neuronal activity, in the infralimbic
medial prefrontal cortex (ILmPFC) [10]. The ILmPFC
is implicated in processing emotional context and, con-
sistent with this notion, human patients with vmPFC
lesions showed impaired social emotions [11]. Add-
itionally, deep brain stimulation of the vmPFC region
can prolong remission of depression in treatment-
resistant patients, indicating a role for this brain region
in depressive states [12,13]. These human data and our
previous findings using chronic psychological stress,
which is known to increase vulnerability to the devel-
opment of depression-like symptoms [14], led us to
initially focus on the ILmPFC to better understand the
neurobiology of stress and how this might potentially
lead to depression sequelae.
To identify as many ILmPFC mechanisms as possible
that are involved in the response to repeated stress, we
used a genome-wide, gene expression analysis ap-
proach. We also chose a restraint stress model as this
type of psychological stress affords greater control in
application of the stressor than with, for example, the
social conflict model. As the neural correlates that
underpin the transition to the depressive state are not
understood, we tried to identify early stress-induced
changes that may increase susceptibility to the develop-
ment of a full depression-like state. It is known that
multiple stress experiences are generally needed to
cause MDD in humans and are absolutely required to
develop depression-like symptoms in animals, so we
used what can be considered a sub-chronic stress para-
digm that does not lead to these behavioural symptoms.
We found sub-chronic stress resulted in a molecular
signature in the ILmPFC, specifically perturbed BDNF-
Ntrk2 (note, Ntrk2 is also known as tyrosine kinase
receptor type B, TrkB) signalling, that is consistent with
known indices of the depressive state and that was
prevented with fluoxetine treatment.Results
Genome-wide gene expression analysis
Illumina RatRef-12 Expression BeadChip microarrays
and GenomeStudio software were used for genome-wide
screening. As gene expression changes are generally
subtle in the brain [15], a relatively low fold-change
cutoff of 1.2 was used. A statistical significance level of
p≤0.05 was used after applying a false discovery rate
(FDR) to correct for multiple testing [16]. Using these
criteria, 263 genes were differentially expressed in the
ILmPFC from the stress group compared to controls,
with 24 genes having significantly higher expression
levels and 239 with significantly lower expression levels
(Table 1). The majority of differentially expressed genes
showed a fold change of less than 3, consistent with the
notion that brain gene expression changes are generally
modest.
Pathways associated with stress-induced gene expression
change
To better interpret the stress-induced changes in gene
expression in the ILmPFC with regard to potential bio-
logical function, the list of differentially expressed genes
was subjected to pathways analysis using the Database
for Annotation, Visualisation and Integrated Discovery
(DAVID) [17]. DAVID analyzes gene lists to statistically
determine whether there is enrichment for genes that
belong to a priori defined gene sets. Using the Kyoto
Encyclopedia of Genes and Genomes (KEGG) - defined
biological pathways, this analysis found enrichment in
the list of genes for 8 pathways (Table 2). Notably, neu-
rotrophin signalling was the most significantly enriched
pathway in the differentially expressed gene list. Two
other pathways associated with neuroplasticity also had
relatively high enrichment scores: long-term potentiation
(LTP) and erbB signalling. Both of these pathways have
been implicated in psychiatric disorders [7,9].
Real-time quantitative PCR (RT-qPCR) confirmation of
stress-induced gene changes
In choosing specific genes for RT-qPCR confirmation,
we used one or more of the following criteria: a) pres-
ence in enriched gene lists, as determined by DAVID
analysis; b) a fold-change in either direction of ≥1.2, as
determined by microarray analysis; c) experimental evi-
dence in the literature supporting an involvement for
the gene of interest in stress-related mechanisms. For in-
stance, microarray and pathway analyses showed a
down-regulation of genes encoding for the neurotrophin
receptors Ntrk3 (−2.28) and Ntrk2 (−1.50) and other
components of the neurotrophin (or Wnt) signalling
pathway such as Camk2a (−1.71), Gsk3β (−1.60) and
Braf (−1.59), in the ILmPFC of rats from the stress
group. RT-qPCR analysis confirmed that the expression
Table 1 Genes identified as differentially expressed by microarray analysis in the IL mPFC of rats submitted to
sub-chronic restraint stress when compared to non-stress control (p≤0.05; 1.2 fold-change cut-off)
Down-regulated genes Up-regulated genes
MAP1B −2.93 RGD1565549 −1.69 MLLT3 −1.55 RGD1306565 −1.44 LOC363380 1.92
BMPR2 −2.83 EEF2K −1.69 RGD1561141 −1.54 RGD1565486 −1.44 LOC360941 1.76
LOC497804 −2.53 NRP1 −1.69 TRIO −1.53 RGD1562123 −1.44 LOC501221 1.68
NTRK3 −2.28 KIF5C −1.69 LOC362543 −1.53 CPD −1.44 ALDH3B1 1.68
LOC497765 −2.24 LARP5 −1.68 LOC497681 −1.53 ASAH3L −1.43 LOC498374 1.62
LOC309928 −2.13 RGD1307100 −1.68 GRIA3 −1.53 NCOA1 −1.43 LOC501224 1.58
MAP2 −2.09 RGD1564560 −1.68 LOC360990 −1.53 LOC291209 −1.42 LOC501093 1.55
HELZ −2.09 TM9SF4 −1.68 GLG1 −1.53 ATRN −1.42 LOC691487 1.54
RICS −2.08 DSCAM −1.68 RBBP6 −1.53 SRRM2 −1.42 LOC367381 1.49
ZFP537 −2.04 PRKCE −1.68 LOC500867 −1.52 CDH9 −1.42 LOC691672 1.47
ODZ4 −2.00 RGD1563437 −1.67 MYT1L −1.52 GPD2 −1.41 LOC501223 1.45
PCDH17 −1.95 USP45 −1.67 JMJD1C −1.52 LOC362315 −1.41 RGD1561850 1.45
ODZ3 −1.95 RGD1308448 −1.66 UNC5C −1.51 KPNB1 −1.41 GS3 1.44
RGD1566031 −1.95 RGD1307907 −1.66 SPON1 −1.51 WDFY1 −1.41 CLCC1 1.39
RIMS1 −1.93 ADD1 −1.65 LOC361942 −1.51 LOC498048 −1.41 LOC690672 1.39
ZFPM2 −1.93 CALN1 −1.65 VPS13D −1.51 SIPA1L1 −1.41 LOC363434 1.39
ODZ3 −1.91 RGD1306245 −1.65 LOC302405 −1.51 RGD1306116 −1.41 LOC501245 1.39
AFF4 −1.89 MTMR9 −1.65 LOC363492 −1.51 ATF7IP −1.40 LOC501089 1.39
LOC290704 −1.89 MYCL1 −1.64 RGD1566279 −1.50 NEO1 −1.40 LOC501399 1.38
APEG3 −1.88 KLF7 −1.64 LPHN1 −1.50 ABCA2 −1.40 RPL7 1.37
SGK −1.85 RERE −1.63 NTRK2 −1.50 CD47 −1.39 LOC691575 1.35
LOC361639 −1.85 RIMS2 −1.62 RGD1563873 −1.49 EHMT1 −1.39 LOC363320 1.35
ANK2 −1.84 TIMP2 −1.62 AKAP9 −1.49 SLC17A7 −1.39
TNR −1.83 SEMA6A −1.61 LRP1 −1.48 NFIA −1.38
FALZ −1.82 KCND2 −1.61 LOC500721 −1.48 RGS17 −1.38
KCNC2 −1.80 LOC497770 −1.60 PIM3 −1.48 RGD1305534 −1.38
LOC501548 −1.79 GSK3B −1.60 LUC7L2 −1.47 ZFP148 −1.37
CENTG1 −1.79 NFIX −1.60 LOC497729 −1.47 CHD3 −1.36
MDGA2 −1.78 GTF2IRD1 −1.60 OPCML −1.46 LOC497754 −1.36
TMOD2 −1.76 PDE10A −1.59 NEGR1 −1.46 BPHL −1.36
LOC501637 −1.76 BRAF −1.59 SLC1A2 −1.46 RELN −1.36
CRIM1 −1.75 SORL1 −1.59 NRIP1 −1.45 LOC362587 −1.35
KLF5 −1.75 PUM1 −1.58 RGD1306101 −1.45 FAM108B1 −1.34
C11ORF8H −1.74 LCP1 −1.57 MYO5A −1.45 USP2 −1.34
SORCS1 −1.74 ZFP57 −1.57 ZDHHC13 −1.45 MAFG −1.33
EDNRB −1.73 ARHGAP5 −1.57 PPFIA3 −1.45 ALCAM −1.33
TOB2 −1.73 LOC313658 −1.57 ATP2B3 −1.45 RGD1307284 −1.32
SLC38A1 −1.72 CSPG4 −1.56 MAST1 −1.45 LOC363849 −1.32
GABRB1 −1.72 LOC683578 −1.56 USP13 −1.45 CAMK2G −1.32
RGD1310722 −1.72 KIF5A −1.56 LOC367779 −1.45 ATP6V0A1 −1.32
PCDH19 −1.71 RGD1311049 −1.56 RGD1307696 −1.44 MPP6 −1.31
CAMK2A −1.71 RGD1308329 −1.56 CELSR2 −1.44 EML2 −1.31
SORCS3 −1.71 SYNJ1 −1.55 DNAJC5 −1.44 LOC501145 −1.30
DUSP8 −1.70 KIF1B −1.55 EPHA5 −1.44
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Table 2 Over-represented KEGG pathways in the ILmPFC, 24h post stress according to DAVID





<0.001 6.239 0.006 0.078 BRAF, RGD1306565, CAMK2G, PTPN11, NTRK3, MAP3K5,
GSK3B, NTRK2, PIK3CA, LOC685605, CAMK2A, LOC685653,
LOC685626, LOC685590
ErbB signaling pathway (04012) 0.003 6.165 0.101 2.694 CBLB, BRAF, GSK3B, CAMK2G, PIK3CA, LOC685605,
CAMK2A, LOC685626, LOC685653, LOC685590
Long-term potentiation (04720) 0.007 6.518 0.169 6.868 GRIN2B, BRAF, CAMK2G, GRIN2A, CAMK2A
Axon guidance (04360) 0.014 4.126 0.252 13.797 EPHA5, SEMA6A, NRP1, PLXNA2, GSK3B, UNC5C
Cell adhesion molecules (04514) 0.025 3.541 0.346 23.766 GLG1, NCAM1, ALCAM, NLGN2, NEO1, NEGR1
Amyotrophic lateral sclerosis (05014) 0.028 5.922 0.332 26.567 SLC1A2, MAP3K5, RGD1306565, GRIN2B, GRIN2A




0.044 4.991 0.375 38.162 SYNJ1, PIK3CA, LOC685605, LOC497978, LOC685626,
LOC685653, PIP4K2B, LOC685590
* = p < 0.05 FDR = false discovery rate.
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and Ntrk3 proteins were decreased in the ILmPFC of
the stress group, in accordance with microarray results
(Figure 1). The decrease in Camk2a gene expression,
however, was not confirmed by RT-qPCR. In addition,
we probed other genes that were not identified by
microarray analysis, but that we considered potentially
important. RT-qPCR showed that expression of Mapk1,
mTOR and Pik3cb genes were all significantly lower in
the stressed group compared to controls. The expression
level of Akt1 was not significantly altered by stress.The effects of fluoxetine on ILmPFC stress-induced gene
changes
As we found significant reduction in BDNF signalling-
related genes in the stress group and perturbation in this
pathway has been implicated in the aetiology of depres-
sion, we determined whether treatment with the anti-
depressant, fluoxetine, would alter the stress-induced
changes in ILmPFC BDNF-related gene expression. As
shown in Figure 1, fluoxetine treatment modulated the
expression levels of genes involved in the neurotrophin
signalling pathway. Fluoxetine significantly reduced the
effect of stress on Ntrk2, Gsk3β and Pik3cb gene expres-
sion in the ILmPFC, such that the levels were not sig-
nificantly different to home cage controls or fluoxetine
treated controls. In contrast, fluoxetine did not alter the
effects of stress on the expression of Ntrk3, mTOR,
Mapk1, and Braf genes. Fluoxetine administration alone
(fluoxetine control animals) also caused a significant de-
crease in expression levels of Ntrk3 and mTOR when
compared to controls without antidepressant or stress
(home cage controls). Fluoxetine, and fluoxetine plus
stress, caused significant and similar increases in
Camk2a mRNA relative to controls and stress.Discussion
Stress is a potent risk factor for the development of de-
pression, but the mechanisms that progress the brain’s
normal response to stress to the pathological state that
manifests as depression are poorly understood. Here, we
have focussed on the ILmPFC to characterise gene ex-
pression changes following repeated, but sub-chronic,
episodes of stress. We based our study design on the
premise that early neurobiological indices of depression,
or at least of the transition into a depression-like state,
may be detectable in a sub-chronic model and we chose
the PFC because of its known sensitivity to stress and its
putative involvement in depression. For instance, stress
causes dendritic remodelling in rat IL [18] and other
mPFC regions [19,20], synaptic plasticity impairment
[21], and deficits in PFC-mediated behaviours [22,23].
Consistent with these preclinical findings, MDD suf-
ferers have reduced neuronal size [24], grey matter
volume [25], and activity [26] in the subgenual PFC, the
neuroanatomical equivalent of the rodent ILmPFC.
To observe depression-like behavioural and other
changes in animals, it is necessary for the animal to ex-
perience repeated exposure to the stressor over pro-
longed periods. For example, in a systematic study of the
effects of stress episode duration and number of repeats,
Kim and Han demonstrated that at least 14 days of 2 hour
daily restraint stress were required to produce significant
depression-like behaviours [27]. Consistent with this
finding, McLaughlin and co-workers found restraint
stress of 6 hours per day for 21 days was required to in-
duce morphological and functional changes in another
brain region affected in depression, the hippocampus
[28]. In a social interaction model, at least 10 consecutive
days of social defeat appear necessary for depression-like
symptomology to appear, at least in a subset of “suscep-
tible” animals [14,29-31]. Similarly, multiple repeats of
Figure 1 A-D Graphs depicting the effects of sub-chronic restraint stress (RST), fluoxetine treatment without stress (FLX), and
fluoxetine treatment with stress (RST+FLX) on gene expression in the ILmPFC. Values are percentage means (±SEM) relative to unhandled
controls (dashed horizontal line at 100%). Sub-chronic restraint stress reduced the transcript levels for the plasma membrane neurotrophin
receptor genes ntrk2 and ntrk3 (A). Note, chronic fluoxetine treatment prevented the stress-induced ntrk2 but not ntrk3 transcript reduction.
Sub-chronic restraint stress reduced transcript levels for the PI3K-AKT1-GSK3B (B) and NTRK2-MAPK/ERK (C) but not the PLCγ1 (D) intracellular
signalling pathways. Interestingly, fluoxetine treatment prevented the sub-chronic stress-induced reduction in PI3K-AKT1-GSK3B signalling
pathway, but not the NTRK2-MAPK/ERK (B-Raf and MAPK1 genes) pathway. Gene expression of the serine-threonine kinase, mTOR, a downstream
target of the PI3K-AKT1 pathway, was reduced by sub-chronic stress, an effect not prevented by fluoxetine (D). * denotes p < 0.05.
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stress model of depression [32]. It should be noted that
single episodes of stress can elicit behavioural changes,
however, these are considered characteristic of anxiety
per se, rather than depression [33,34]. With respect to
anxiety, we cannot completely discount the possibility
that our sub-chronic stress-induced molecular changes
are also related to anxiety. The link between stress and
anxiety is well-established and there is considerable over-
lap in the putative mechanisms and behaviours between
anxiety and depression. Furthermore, some antidepres-
sants also have anxiolytic properties. Regarding this pos-
sibility, there is conflicting evidence in the literature. It is
known that a single restraint episode, for example, can
result in the delayed appearance of anxiety-like behaviour
[35], and Kim and Han (2006) demonstrated that animals
subjected to a more chronic restraint stress paradigm
(6h/day for 10 consecutive days) did not display anxiety
related behaviours as assessed with the elevated plus
maze [27]. One explanation is that acute stress episodesare more likely to induce anxiety like behaviours and as
the stress becomes more chronic there is a transition to a
more depression-like behavioural phenotype. However,
others have shown that anxiety-like behaviours can be
displayed, in addition to depression-like ones, after many
weeks of chronic restraint stress [36]. Clearly, more work
needs to be done to understand the relationship between
the nature of stress (type, intensity, duration, frequency)
and the development of anxiety and depression. A poten-
tial limitation of the present study concerns the lack of a
single acute stress group for comparison with the control
and sub-chronic groups. Notionally, this type of acute
stressor might have caused a similar molecular profile.
However, we consider this possibility to be extremely un-
likely given that Bland et al. (2007) used a single 80
minute session of electric shock, a stressor that is far
more intense than our restraint stress, and found the
stressed induced changes in neurotrophin transcripts in
all regions of the mPFC, including ILmPFC, had returned
to baseline by 24 hours post-stress [37].
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tially lead to the development of pathology, we first car-
ried out a genome-wide gene expression analysis using
moderately stringent criteria to define differentially
expressed genes. A number of previous studies have also
taken this approach [38], but direct gene-by-gene com-
parisons with these studies is problematic due to the dif-
ferent stress paradigms and microarray platforms used,
as well as variation in brain region taken for analysis. In-
deed, Surget and colleagues showed remarkably little
overlap (zero genes for 3-region overlap) in gene expres-
sion between the cingulate cortex, amygdala and dentate
gyrus of chronically stressed animals [39]. With regard
the pattern of gene expression, we found the vast major-
ity of differentially expressed genes were down-regulated,
with most of the up-regulated transcripts being predicted
genes or pseudogenes. Down regulation of a majority of
genes in the PFC has also been observed following
chronic stress [40,41]. To improve interpretability of the
microarray data in relation to gene function in biological
processes, we carried out pathway analysis whereby the
degree to which sets of genes belonging to a priori deter-
mined biological pathways were enriched in the differen-
tially expressed gene list was assessed using DAVID
[17,42,43]. We identified eight significantly enriched
pathways (Table 2), three had FDRs less than 10% and we
focussed on these. Notably, all three of these pathways
have been implicated in neuropsychiatric disorders [7,9].
The most significantly enriched pathway, and the one
with the lowest FDR, was for neurotrophin signalling.
There is a substantial body of evidence implicating
BDNF in MDD. For example, BDNF and Ntrk2 tran-
scripts and protein levels were markedly reduced in the
PFC and amygdala of MDD subjects [44,45]. Also, serum
BDNF is lower in MDD sufferers [46] and BDNF is being
considered a predictive diagnostic marker for MDD [47].
Additionally, a number of chronic stress-based animal
models of MDD have shown perturbation in the BDNF-
Ntrk2 signalling pathway in various brain regions [48-50].
Indeed, Nestler and colleagues have demonstrated a cru-
cial role for BDNF in the mesolimbic system for the de-
velopment of depression-like behaviour [14,29]. We did
not find stress-induced change in BDNF transcript levels
in ILmPFC, which may imply that BDNF protein levels
are also unchanged. This raises the question as to why
Ntrk2 levels should change if BDNF does not. One pos-
sibility is that BDNF protein is delivered by dopamin-
ergic afferents [14,29,51] to the ILmPFC and, consistent
with this notion, we have found increased BDNF tran-
script levels in VTA dopamine neurons (manuscript in
preparation). Alteration in the BDNF pathway can also
be observed in some acute stress models, however as
mentioned above, these changes are typically short-lived
[37,52-55]. Our altered BDNF-Ntrk2 pathway findingwas evident at 24 hours post the last stress episode of
the sub-chronic stress paradigm and is consistent with a
molecular signature of depression. The sub-chronic
stress paradigm used in the present study does not in-
duce depression-like behaviours, therefore, this molecu-
lar finding may represent an early mechanistic indicator
of depression neuropathology. Prevention of the sub-
chronic stress-induced BDNF-Ntrk2 perturbation by the
antidepressant, fluoxetine, is consistent with this notion.
Furthermore, it may also indicate that the ILmPFC is a
particularly sensitive region to stress and therefore im-
portant in the development of the depressive state.
BDNF (or NT3/4) binding to Ntrk2 can activate three
main intracellular signalling cascades: mitogen-associated
protein kinase (MAPK; also known as the Ras/ERK-
MAPK pathway), phosphotidylinositol-3 kinase (PI3K) -
Akt, and the phospholipase C-γ1 (PLCγ1) cascades
[56,57]. As Ntrk2 is the post-synaptic entry point to the
BDNF/Ntrk2 signalling cascade, reduced ntrk2 levels
might be expected to affect each of these intracellular sig-
nalling cascades and have significant impact on diverse
cell functions. Indeed, genetically reduced BDNF/Ntrk2
levels result in altered activity-dependent synaptogenesis
[58], synaptic function, such as LTP [59,60], learning [59]
and, importantly, stress-related behaviours [61]. Our RT-
qPCR data indicate that sub-chronic stress induced re-
duction in Ntrk2 transcript levels may in fact not impact
each of these signalling pathways. For example, both the
PI3K-Akt (PIK3CB and GSK3B genes) and MAPK/ERK
(B-Raf and MAPK1 genes) pathways were affected by
sub-chronic stress, but the PLCγ1 (CAMK2A gene) was
spared. One important downstream target of the PI3K-
Akt and MAPK/ERK pathways is the mammalian target
of rapamycin (mTOR), a kinase involved in many cellular
processes [62], including translation of synaptic proteins
that underpin plasticity [63], and, therefore, potentially
important in the development of the depressive state [9].
Although mTOR was not identified as being differen-
tially expressed by microarray, using RT-qPCR we found
it to be significantly reduced, consistent with changes in
the aforementioned upstream regulatory pathways. This
is supportive for a potential role in maladaptive neuronal
plasticity contributing to the depressive state, although
this will obviously require further experimental elucida-
tion, particularly at the protein level.
Interestingly, antidepressant treatment with fluoxetine
only prevented the sub-chronic stress-induced changes
in the PI3K-Akt pathway related transcripts (PIK3CB
and GSK3B genes), with B-RAF and MAPK1 gene tran-
scripts of the MAPK/ERK pathway not significantly dif-
ferent to the stress without fluoxetine levels. This may
indicate that the effects of fluoxetine antidepressant
treatment are preferentially mediated by the PI3K-Akt
pathway, at least in this brain region, and suggest that
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therapeutic interest. In this regard it is notable that
GSK3B has been implicated in the pathophysiology of
mood disorders [8,64]. For example, GSK3B is one target
for the mood-stabilising drug lithium, it is also required
for the antidepressant effects of ketamine [65], and in
MDD sufferers, GSK3B kinase activity is increased in
the PFC [66]. Consistent with a role for GSK3B in de-
pression, fluoxetine increases phosphorylation of GSK3B
at a specific N-terminal serine residue, thereby decreas-
ing the kinase’s activity [67]. Conversely, increasing
GSK3B activity through viral-mediated overexpression,
induces a depression-like phenotype in an animal model
[68]. How a reduction in GSK3B at the transcript level,
as seen in the present study, fits into this scheme is not
clear. Interestingly though, and consistent with our data,
GSK3B gene expression but not protein levels, was
reduced in the nucleus accumbens of depression-
susceptible animals in a chronic social defeat model of
depression [68]. This similarity between our GSK3B
finding and that of Wilkinson et al., 2011 [68], further
supports our contention that we are seeing an early mo-
lecular signature of depression in the sub-chronic stress
model. It should also be noted that GSK3B is not limited
to the BDNF/Ntrk2 pathway as it is an important com-
ponent of the Wnt-Frizzled signalling cascade, as well as
being a downstream target of PKA, PKC and Akt [69],
all of which are components of multiple signalling cas-
cades. The Wnt-Frizzled signalling pathway has recently
been implicated in depression [68,70].
We also found sub-chronic stress reduced ILmPFC
transcript levels for Ntrk3, the cognate receptor for the
neurotrophin, NT-3. Like BDNF, NT-3 has also been
implicated in MDD. For instance, NT-3 gene expression
was reduced in peripheral blood cells of individuals dur-
ing depressive but not remissive states [71] and Ntrk3
transcript and protein levels were reduced in some brain
regions of MDD patients [72] as were NT-3 levels [73].
Surprisingly, we found fluoxetine alone also reduced the
expression of Ntrk3. Previously, it was shown that SSRI
treatment had no effect on CSF NT-3 protein levels in
MDD [74] and transcript levels in rat hippocampus [75].
The Ntrk3 transcript reduction seen in the present study
may reflect a similar mechanism to that causing Ntrk2
reduction. Why this particular receptor was affected by
fluoxetine remains to be determined.
Conclusions
To further elucidate potential neurobiological mechan-
isms that may increase depression susceptibility, we have
used a sub-chronic stress paradigm that is not capable of
inducing behaviours that are characteristic of depression,
and evaluated the infralimbic prefrontal cortex for mo-
lecular indices that may constitute an early signature forthis psychopathology. We found that the BDNF-Ntrk2
pathway was affected by the stress paradigm as was
GSK3B, which is a component of both the neurotrophin
as well as the Wnt signalling cascades. Both the Ntrk2
and Wnt signalling pathways are implicated in depres-
sion and, consistent with the notion that our molecular
findings represent early depression neuropathology, the
stress-induced perturbations in these pathways were pre-
vented by pretreatment with an antidepressant, fluoxet-
ine, a selective serotonin reuptake inhibitor. These
findings indicate that brain signalling pathways that are
known to be abnormal in fully developed depressive
states are actually perturbed well before the manifest-
ation of behaviours that characterise depression.
Methods
Animals
Adult, male, Sprague–Dawley rats (20–22 weeks of age)
were used for all experiments. Animals were obtained
from the Animal Services Unit at the University of New-
castle, group-housed (4 per cage) on arrival and main-
tained in a temperature (21°C ± 1) and humidity
controlled environment with food and water available ad
libitum. Lighting was set for a 12:12 hour reverse light–
dark cycle (lights off at 7:00AM; lights on at 7:00PM).
All procedures were conducted in the dark phase. Ani-
mal housing and procedures were carried out in strict
accordance with the University of Newcastle’s Animal
Care and Ethics Committee regulations, the NSW Ani-
mal Research Act and Regulations, and the Australian
Code of Practice for the care and use of animals for sci-
entific purposes.
Experimental procedures
Stress treatment: After a minimum of one week for accli-
matisation, rats were randomly assigned to experimental
groups (n = 6 per group) and housed 2 per cage. The con-
trol group consisted of animals that were maintained,
without handling, under normal housing conditions until
the day of sacrifice. We kept our control group as stress-
naïve as possible in order to improve the probability of
detecting subtle stress-related changes in the brain. It is
known that handling alone is stressful to animals, al-
though in the context of handling related stress and the
mPFC, it has been shown that 7 days of handling rats for
restraint stress did not alter mPFC pyramidal neuron den-
drite morphology [20]. Animals in the stress group were
subjected to a sub-chronic stress regimen that consisted
of the handling necessary for and the daily sessions of
1 hour restraint in a Plexiglas tube (7.5 × 18 cm), for
5 consecutive days. There are many stress paradigms that
can be used in pre-clinical studies of depression, however,
they all suffer various limitations and there is no consen-
sus as to which is the optimal one [76]. Restraint stress is
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that is, in part, psychogenic, and one advantage of this
stress method is the ability to readily control stressor
parameters (intensity, duration, frequency), although, as
with all stress paradigms, the individual animal’s stress re-
sponse is not controllable. Importantly, we and others
have shown chronic restraint stress can induce
depression-like behaviours (e.g. anhedonia) and synaptic
changes thought to contribute to these behaviours (e.g.
dendritic retraction and impaired synaptic plasticity)
[21,23,27]. Furthermore, the antidepressant fluoxetine has
been shown to prevent development of depression-like
behaviours following chronic restraint stress [77]. Taken
together, these findings indicate the restraint stress model
has a certain degree of construct, face and predictive val-
idity [76] and is suitable for a sub-chronic exposure para-
digm. The stress protocol was initiated at 10 a.m. each
day and animals were returned to their pair-housed cage
condition immediately after session completion. Animals
were killed by an overdose of pentobarbitone (LethabarbW)
24h after the last stress session. Food and water were avail-
able ad libitum in home cages.
Chronic fluoxetine treatment: Selective serotonin re-
uptake inhibitors (SSRIs) have been an important class
of drugs for the treatment of depression ever since the
introduction of fluoxetine, the original member of this
class approved to treat humans. Much debate continues
regarding the relative efficacies within and between the
various classes of antidepressants, not to mention the
specific molecular targets, intended and non-intended,
of the antidepressants. Suffice to say, long-term treat-
ment with SSRIs like fluoxetine, has been shown to sig-
nificantly reduce the risk of relapse of depression [78]
and, importantly, in the context of the present study, flu-
oxetine can prevent chronic stress induced brain BDNF
deficits [50]. To assess the effect of fluoxetine anti-
depressant on ILmPFC gene expression following sub-
chronic stress, a second batch of rats was randomly
assigned into 2 groups (n = 6 per group) and in order to
avoid injection stress, fluoxetine was administered via
drinking water for 21 days prior to the start of the sub-
chronic stress protocol. Rats were pair-housed to avoid
social isolation stress. To deliver a target dose of ap-
proximately 10mg/Kg/day of fluoxetine hydrochloride
((7)-N-methyl-g-(4-[trifluoromethyl]-phenoxy)-benzene-
propanamine), the average daily water intake was mea-
sured over a period of 4 days and the appropriate
concentration of the drug then calculated to be delivered
in that volume. Administration of fluoxetine at this dose,
via drinking water to group-housed animals (up to 7 rats
per cage), has been shown to be efficacious [79,80] and
we have previously found this method results in a
plasma fluoxetine concentration of 267 ±50 ng/ml
(mean ± SEM; unpublished data). Body weight and drugsolution intake were recorded daily throughout the
period of fluoxetine administration. Fluoxetine treat-
ment was maintained throughout the stress regimen
until rats were killed at the end of the experiment. The
fluoxetine control group received the same drug treat-
ment but animals were maintained, without handling,
under normal housing conditions until the day of sacri-
fice. Both groups had access only to fluoxetine-treated
water for the duration of the experiment. Food was
available ad libitum.
Tissue preparation and RNA extraction
After decapitation and craniotomy, the brain was rapidly
removed and cooled in ice-cold diethyl pyrocarbonate
(DEPC)-treated PBS. Brains were then placed in an ice-
cold metal brain matrix and the frontal lobe separated in
the coronal plane and instantly frozen in dry-ice chilled
isopentane. Tissue was stored at −80°C until needed.
A series of 500 μm-thick coronal cryosections were
obtained through the rostrocaudal extent of the ILmPFC
(+2.5 to +4.0 mm relative to Bregma) [81]. Sections were
then placed onto chilled RNAse-free glass microscope
slides and the ILmPFC bilaterally excised using a 0.8
mm diameter stainless steel punch. ILmPFC tissue
punches were obtained from three brain sections, pooled
and homogenized with a motorized pestle in a RNAse-
free microtube containing 350 μl of RNA lysis buffer
(Qiagen). Homogenised samples were stored at −80°C
until needed. Total RNA was then extracted and con-
taminating genomic DNA (gDNA) removed by in-
solution DNase digestion followed by RNA Cleanup.
RNA extraction, clean up and DNA digestion were done
using RNeasyW Micro Kit and DNase reagents (Qiagen)
according to manufacturer’s instructions. RNA yield and
purity were estimated by absorbance spectrophotometry
(NanoDrop 1000; Thermo Scientific). RNA integrity was
evaluated by qPCR comparison of the relative levels of the
30 and 50 ends of the transcripts for the housekeeping genes
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
β-actin (primers are listed in Table 3), as previously
described [82]. RNA samples were further processed for
either microarray hybridization or real-time, quantitative
polymerase chain reaction (RT-qPCR).
Gene expression microarray data processing
Microarrays were processed by the Australian Genomics
Research Facility (AGRF; Melbourne, Australia). 100ng
of total RNA, obtained from the ILmPFC was used for
microarray analysis. For microarray analysis we used
RNA from 4 of the 6 animals in each group, whereas for
qPCR, RNA from each of the 6 animals was used. RNA
quality was first checked using an Agilent Bionalyser,
and then prepared for hybridization onto Illumina
RatRef-12 Expression BeadChips. Arrays were scanned
Table 3 Primers used for validation of stress-responsive genes by RT-qPCR
Gene ID Symbol Sense (50-30) Antisense (50-30) Amplicon
size (bp)
18S ribosomal RNA Rn18s CCCGAAGCGTTTACTTTGAA CCCTCTTAATCATGGCCTCA 136
Glyceraldehyde-3-phosphate dehydrogenase Gapdh GAAGGGCTCATGACCACAGT GGATGCAGGGATGATGTTCT 117
Actin, beta Actb CACACTGTGCCCATCTATGA CCGATCGTGATGACCTGACC 272
Calcium/calmodulin-dependent protein
kinase II alpha
Camk2a GCCTGGACTTTCATCGATTC GGTACTGAGTGATGCGGATGT 141
Glycogen synthase kinase 3 beta Gsk3β GCGAGACACACCTGCCCTCTTC GTGGCCAGAGGTGGGTTACTTGAC 66
Mammalian target of rapamycin
(serine/threonine kinase)
mTOR TTGGATGTTCCAACCCAAGT CAGGCCTTGGTTACCAGAAA 106
Neurotrophic tyrosine kinase, receptor, type 2 Ntrk2 TGGAGGGCGACCCACTCATCA TCAGCTCGG TGGGCGGGTTA 123
Neurotrophic tyrosine kinase, receptor, type 3 Ntrk3 CATCCGCTGGATGCCACCTGAAA AAGACACGGCCTTGGGTGATGCA 50
Phosphoinositide-3-kinase, catalytic, beta polypeptide Pik3cb CCTGCGACAGATGAGTGATG CAATCCTCCGGTTGTCAAGT 134
V-raf murine sarcoma viral oncogene homolog B1 Braf CATGGCGACGTGGCAGTGAAAATG TGAGGTGTGGGTGCTGTCACATTC 50
Glyceraldehyde-3-phosphate dehydrogenase-3-prime Gapdh-30 GGCTGGCATTGCTCTCAA GAGGTCCACCACCCTGTTG 88
Glyceraldehyde-3-phosphate dehydrogenase-5-prime Gapdh-50 GACAGCCGCATCTTCTTG CACCGACCTTCACCATCTTG 63
Actin, beta-3-prime Actb-30 CCTAGCACCATGAAGATCAAGA GCCAGGATAGAGCCACCAATC 77
Actin, beta-5-prime Actb-50 ACCCAGATCATGTTTGAGACCTT CAGAGGCATACAGGGACAAC 79
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microarrays probe for 21,910 genes. Raw intensity data
was then imported into Illumina GenomeStudio Data
Analysis Software and statistical analysis of gene expres-
sion was carried out using the Gene Expression module
(version 1.1.1). First, a background measure based on
the average signal of negative control probes was
obtained and subtracted from all probes of the array.
Next, the data was normalized by the GenomeStudio
Average Normalization algorithm to adjust sample sig-
nals and minimize variation arising from non-biological
factors. The p-values for differential expression were
then calculated using the Illumina Custom Error Model
algorithm and the Benjamini and Hochberg false discov-
ery rate (FDR), a multiple testing correction method for
adjustment of p-values [16]. Genes were considered to
be differentially expressed if the comparison resulted in
a p-value ≤ 0.05 and a ≥ 1.2 fold-change in expression
(in either direction).
Real-time quantitative polymerase chain reaction
(RT-qPCR)
For confirmation of gene expression changes, RT-qPCR
was carried out on mRNA from all 6 animals of each
group. Gene-specific primer pairs (Table 3) were
designed with the web-based NCBI primer-BLAST soft-
ware (http://www.ncbi.nlm.nih.gov/tools/primer-blast/),
and targeted sequence near the 30 end of the cDNA and,
where possible, amplicons spanned intron:exon boundar-
ies. cDNA was generated by reverse transcription using
SuperScript III (Invitrogen) according to manufacturer’sinstructions. Briefly, 200ng of total RNA, 1μl of 50μM)
oligo(dT)20 primer, 0.5μl of 20μM 18S RNA-specific pri-
mer (50-GAACTACGACGGTATCTGA-30), 1μl of 10mM
dNTP, and molecular biology grade water to 13μl, were
mixed and heated for 5 minutes at 65°C, then chilled on
ice for 1 minute. 4μl 5X First-Strand Buffer, 1μl of 0.1M
DTT, 1μl RNaseOUT (40 units/μl) and 1μl SuperScript
III RT (200 units/μl) were added and the mixture incu-
bated for 60 minutes at 50°C, followed by 15 minutes at
70°C. Reverse transcription reactions without reverse
transcriptase were also done to assess gDNA contamin-
ation. qPCR reactions were carried out in 12μl volumes
containing: 6μl 2X SensiMixPlus SYBR (Quantace);
200nM each of forward and reverse primers, except for
18S rRNA, where 1μM was used; 1ng cDNA; molecular
biology grade water to 12μl. After an initial 10 minute,
95°C enzyme activation step, 40 cycles of 95°C for 30 sec
(step 1) followed by 60°C for 31 sec (step 2) were com-
pleted. Only primers that produced a single amplified
product as shown by melt curve and gel electrophoresis
analyses were used. Reactions were carried out on an
ABI 7500 Real-Time PCR System (Applied Biosystems)
and analyzed using the Applied Biosystems 7500 Se-
quence Detection Software (Version 1.4). Relative ex-
pression levels were determined using the comparative
Ct method (ΔΔCt; [83], where gene expression was first
normalised to the average of 18S rRNA, GAPDH and
β-actin, to generate a ΔCt for each gene and sample, and
then the average ΔCts for each gene were compared be-
tween the various groups. Statistical analysis of relative
gene expression was done by comparisons between
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to the alpha level to control for family-wise error.
Pathway analysis
Pathway analysis of differentially expressed genes was
undertaken using the Database for Annotation, Visual-
ization, and Integrated Discovery bioinformatics resource
(DAVID; http://david.abcc.ncifcrf.gov/; [17]. DAVID is a
gene-centered database that integrates gene annotation
resources and facilitates high-throughput gene functional
analysis by conferring biological meaning to a gene. En-
richment analysis was performed in the “Pathway” anno-
tation category primarily using the Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway database for
annotated terms. All other analysis parameters were left
as the default. For a detailed description of the algo-
rithms and statistical parameters used by DAVID for
enrichment results see [42].
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